Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Gliosarcoma 1Glioblastoma 1

Interventions

Cyclophosphamide 29fludarabine 19Rituximab 15fludarabine phosphate 12Specimen Handling 8obinutuzumab 7Immunotherapy, Adoptive 7Lenalidomide 6Etoposide 6pirtobrutinib 5ibrutinib 5glofitamab 5axicabtagene ciloleucel 5Whole-Body Irradiation 5Mycophenolic Acid 5venetoclax 4polatuzumab vedotin 4Prednisone 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Doxorubicin 4Blood Component Removal 4Biopsy 4pembrolizumab 3daratumumab 3X-Rays 3Vincristine 3Stem Cell Transplantation 3Interleukin-2 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Non-Hodgkin × efineptakin alfa × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡